

SUBLOCADE - (100MG/0.5ML, 300MG/1.5ML ; SOLUTION,EXTENDED RELEASE)

Generic Name	BUPRENORPHINE	Innovator	INDIVIOR INC
Dosage	100MG/0.5ML, 300MG/1.5ML ; SOLUTION,EXTENDED RELEASE	Branded US Sales	Less Than \$1000 mn
Probable FTF	None	Known Para IV Filers	None
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	SUBLOCADE contains buprenorphine, a partial opioid agonist, and is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a buprenorphine containing product, followed by dose adjustment for a minimum of 7 days. SUBLOCADE should be used as part of a complete treatment program that includes counseling and psychosocial support.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.